On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in this space expected to heat up in 2023. Possible biosimilar launches for 2020 which were discussed include pegfilgrastim, bevacizumab and rituximab.
Full Court Clarifies and Recalibrates the Obviousness Test for “Pre-Raising the Bar” Patents
Sandoz AG v Bayer Intellectual Property GmbH [2024] FCAFC 135 Date of decision: 23 October 2024 Body: Full Court of the Federal Court of...